News & Updates
Filter by Specialty:

Paternal IBD medication use before conception carries no excess risk of childhood infections
Fathers’ exposure to anti-inflammatory or immunosuppressive medications for inflammatory bowel disease (IBD) prior to conception does not appear to contribute to a significantly increased risk of childhood infections, a study has found.
Paternal IBD medication use before conception carries no excess risk of childhood infections
28 Jul 2022
Short-course quinolones, pivmecillinam on par with standard regimens in uncomplicated cystitis
For women with acute uncomplicated cystitis, treatment regimens that include third- and fourth-generation quinolones and pivmecillinam can be administered in shorter courses, which perform similarly to the currently recommended regimens in terms of achieving symptomatic cure, according to the results of a meta-analysis presented at the 37th Annual European Association of Urology (EAU) Congress.
Short-course quinolones, pivmecillinam on par with standard regimens in uncomplicated cystitis
27 Jul 2022
Maternal vaccination reduces COVID-19 hospitalization risk in offspring
Full vaccination (two doses) with an mRNA COVID-19 vaccine during pregnancy was associated with a reduced risk of COVID-19-related hospitalization among infants younger than 6 months of age, according to a recent study.
Maternal vaccination reduces COVID-19 hospitalization risk in offspring
27 Jul 2022
Myopericarditis risk after COVID-19 vaccine not greater than after other vaccines
The risk of myopericarditis after COVID-19 vaccination is not greater than that following other non–COVID-19 vaccinations, according to a systematic review and meta-analysis conducted by researchers in Singapore.
Myopericarditis risk after COVID-19 vaccine not greater than after other vaccines
26 Jul 2022
UltraVIOLET: Oteseconazole turns in satisfactory results for recurrent yeast infection
In the treatment and prevention of recurrent yeast infection or vulvovaginal candidiasis, oteseconazole performs similarly to standard-of-care fluconazole but better as compared with placebo, as shown in the results of the phase III ultraviolet study.
UltraVIOLET: Oteseconazole turns in satisfactory results for recurrent yeast infection
26 Jul 2022
Abrocitinib safe, effective in moderate-to-severe atopic dermatitis after dupilumab use
Treatment with abrocitinib is both safe and effective in patients with moderate-to-severe atopic dermatitis (AD), regardless of prior dupilumab response status, a study has shown.
Abrocitinib safe, effective in moderate-to-severe atopic dermatitis after dupilumab use
26 Jul 2022
Empagliflozin shows promise for chronic SIAD-induced hyponatremia
The sodium-glucose cotransporter 2 inhibitor empagliflozin showed potential as a treatment alternative for hyponatremia due to chronic syndrome of inadequate antidiuresis (SIAD), according to a trial presented at ENDO 2022.